Therapy paused (N = 59) n (%) | Therapy continued (N = 148) (%) | p-value | |
---|---|---|---|
Gender | |||
Male | 10 (17.5) | 50 (34.0) | 0.0261 |
Female | 47 (82.5) | 97 (66.0) | |
Age, years | |||
Mean (sd) | 52.3 (11.1) | 51.8 (14.8) | 0.7693 |
< 40 | 9 (15.3) | 35 (23.8) | 0.0192 |
40–65 | 45 (76.3) | 82 (55.8) | |
> 65 | 5 (8.5) | 30 (20.4) | |
School education | |||
Lower | 6 (10.7) | 10 (7.1) | 0.6892 |
Middle | 15 (26.8) | 44 (31.2) | |
Upper | 36 (62.5) | 85 (60.3) | |
Other | 0 (0) | 2 (1.4) | |
Previous COVID-19 infection | |||
Yes | 1 (1.7) | 2 (1.4) | 11 |
First administered vaccine | |||
BNT162b2 (Pfizer/BioNTech) | 36 (65.5) | 95 (68.3) | 0.8282 |
AZD 1222 (AstraZeneca) | 12 (21.8) | 30 (21.8) | |
mRNA-1,273 (Moderna) | 7 (12.7) | 14 (10.1) | |
Good Subjective Health statusa | 28 (47.5) | 93 (62.8) | 0.0601 |
Good Quality of Lifea | 32 (54.2) | 92 (62.2) | 0.3461 |
PHQ-4D > 5 | 9 (15.0) | 22 (15.3) | 11 |